These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17443441)

  • 1. [Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].
    Ellrichmann G; Russ H; Müller T
    Fortschr Neurol Psychiatr; 2007 Jul; 75(7):387-96. PubMed ID: 17443441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.
    Müller T; Russ H
    Expert Opin Pharmacother; 2006 Sep; 7(13):1715-30. PubMed ID: 16925499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of motor dysfunction in Parkinson's disease: an overview.
    Thobois S; Delamarre-Damier F; Derkinderen P
    Clin Neurol Neurosurg; 2005 Jun; 107(4):269-81. PubMed ID: 15885384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Initial management and adaptation of Parkinson's disease treatment].
    Gérard JM
    Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management for motor and non-motor complications in late Parkinson's disease.
    Chan DK; Cordato DJ; O'Rourke F
    Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor complications of Parkinson's disease.
    Martignoni E; Riboldazzi G; Calandrella D; Riva N
    Neurol Sci; 2003 May; 24 Suppl 1():S27-9. PubMed ID: 12774208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which factors influence therapeutic decisions in Parkinson's disease?
    Baas H; Fuchs G; Gemende I; Hueber R; Lachenmayer L; Schneider E; Schoenberger B; Werner M
    J Neurol; 2002 Oct; 249 Suppl 3():III/49-52. PubMed ID: 12522573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classifying risk factors for dyskinesia in Parkinson's disease.
    Sharma JC; Bachmann CG; Linazasoro G
    Parkinsonism Relat Disord; 2010 Sep; 16(8):490-7. PubMed ID: 20598622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.